Brain eQTLs of European, African American, and Asian ancestry improve interpretation of schizophrenia GWAS

- 3 Yu Chen^{1,2,16}, Sihan Liu^{1,3,16}, Zongyao Ren¹, Feiran Wang¹, Yi Jiang¹, Rujia Dai⁴, Fangyuan
- 4 Duan¹, Cong Han¹, Zhilin Ning⁵, Yan Xia⁶, Miao Li¹, Kai Yuan², Wenying Qiu⁷, Xiao-Xin Yan
- ⁵⁸, Jiapei Dai⁹, Richard F. Kopp⁴, Jufang Huang⁸, Shuhua Xu¹⁰, Beisha Tang¹⁴, Eric R.
- 6 Gamazon¹¹, Tim Bigdeli¹², Elliot Gershon¹³, Hailiang Huang², Chao Ma^{7*}, Chunyu Liu^{1,4*}, and
- 7 Chao Chen ^{1,14,15*}
- 8 ¹MOE Key Laboratory of Rare Pediatric Diseases & Hunan Key Laboratory of Medical Genetics,
- 9 School of Life Sciences, and Department of Psychiatry, The Second Xiangya Hospital, Central
- 10 South University, Changsha, Hunan 410000, China.
- ² Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- ³ Institute of Rare Diseases, West China Hospital, Sichuan University, Chengdu, China.

⁴ Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA.

- 14 ⁵ Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health,
- 15 University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
- ⁶ Hunan Key Laboratory of Molecular Precision Medicine, Department of Neurosurgery, Xiangya
- 17 Hospital, and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South
- 18 University, Changsha, Hunan, China.
- ⁷ Institute of Basic Medical Sciences, Neuroscience Center, National Human Brain Bank for
- 20 Development and Function, Chinese Academy of Medical Sciences; Department of Human

21 Anatomy, Histology and Embryology, School of Basic Medicine, Peking Union Medical College,

- 22 Beijing, China.
- ⁸ Department of Human Anatomy and Neurobiology, Xiangya School of Medicine, Central South
- 24 University, Changsha, China.
- ⁹ Wuhan Institute for Neuroscience and Engineering, South-Central University for Nationalities,
- 26 Wuhan, China.
- ¹⁰ State Key Laboratory of Genetic Engineering, Center for Evolutionary Biology, Collaborative
- 28 Innovation Center of Genetics and Development, School of Life Sciences, Fudan University,
- 29 Shanghai, China.
- 30 ¹¹ Division of Genetic Medicine Vanderbilt University School of Medicine Nashville, USA
- ¹² Institute for Genomics in Health, SUNY Downstate Health Sciences University, Brooklyn, New
 York, USA
- ¹³ Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL,
 USA
- ¹⁴ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South
 University, Changsha, China.
- ¹⁵ Hunan Key Laboratory of Animal Models for Human Diseases, Central South University,
 Changsha, China.
- ¹⁶ These authors contributed equally: Yu Chen, Sihan Liu.
- 40 *Corresponding author. Email: <u>machao@ibms.cams.cn</u> (C.M.); <u>LiuCh@upstate.edu</u> (C.L.);
- 41 <u>chenchao@sklmg.edu.cn</u> (C.C.)

43 Abstract

44 Research on brain expression quantitative trait loci (eQTLs) has illuminated the genetic 45 underpinnings of schizophrenia (SCZ). Yet, the majority of these studies have been centered on 46 European populations, leading to a constrained understanding of population diversities and disease 47 risks. To address this gap, we examined genotype and RNA-seq data from African Americans (AA, 48 n=158), Europeans (EUR, n=408), and East Asians (EAS, n=217). When comparing eQTLs 49 between EUR and non-EUR populations, we observed concordant patterns of genetic regulatory 50 effect, particularly in terms of the effect sizes of the eQTLs. However, 343,737 cis-eQTLs 51 (representing ~17% of all eQTLs pairs) linked to 1,276 genes (about 10% of all eGenes) and 52 198,769 SNPs (approximately 16% of all eSNPs) were identified only in the non-EUR populations. 53 Over 90% of observed population differences in eQTLs could be traced back to differences in 54 allele frequency. Furthermore, 35% of these eQTLs were notably rare (MAF < 0.05) in the EUR 55 population. Integrating brain eQTLs with SCZ signals from diverse populations, we observed a 56 higher disease heritability enrichment of brain eQTLs in matched populations compared to 57 mismatched ones. Prioritization analysis identified seven new risk genes (SFXN2, RP11-282018.3, CYP17A1, VPS37B, DENR, FTCDNL1, and NT5DC2), and three potential novel regulatory 58 59 variants in known risk genes (CNNM2, C12orf65, and MPHOSPH9) that were missed in the EUR 60 dataset. Our findings underscore that increasing genetic ancestral diversity is more efficient for 61 power improvement than merely increasing the sample size within single-ancestry eQTLs datasets. Such a strategy will not only improve our understanding of the biological underpinnings of 62 63 population structures but also pave the way for the identification of novel risk genes in SCZ.

64 Keywords: eQTLs; Schizophrenia; GWAS signals; Population diversity

65 Introduction

66 Genome-wide association studies (GWAS) have identified 287 risk loci associated with 67 schizophrenia (SCZ)¹. Yet, the underlying mechanisms of these loci in disease development and 68 progression remain poorly understood. Primarily, over 80% of GWAS risk loci reside in non-69 coding regions, devoid of protein-coding sequences, making it challenging to attribute them to 70 specific genes. Moreover, predicting the regulatory effect of these loci proves challenging due to 71 their tendency for gene-specific and tissue-specific effects. One effective strategy for gaining 72 insights into their functions involves the integration of SCZ GWAS signals with expression 73 quantitative trait loci (eQTLs), utilizing genotype and expression data from post-mortem brains. These brain eQTLs establish crucial links between risk genomic regions and gene expression levels. 74 75 prioritizing potential disease risk genes through methods such as colocalization and transcriptome-76 wide association study (TWAS).

77 Past brain eQTL studies primarily focused on European (EUR) ancestry²⁻⁶. Global population 78 diversity has not been adequately represented. Cross-population studies have shown that these 79 European ancestry based models do not effectively predict gene expression in other ancestral 80 groups⁷. This limitation weakens the power to detect TWAS associations in genetically diverse 81 samples. While multi-ancestry eOTL meta-analyses in the human brain improve statistical power 82 in uncovering risk loci shared across populations, key genetic variants regulating expression in 83 specific underrepresented populations remain largely uncharted. The benefits of having brain eQTLs in diverse populations have not been thoroughly documented. Identifying eQTLs specific 84 85 to biomedically underrepresented groups like African Americans (AA) and East Asians (EAS) can 86 better understand the genetic contributions to disease susceptibilities and outcomes in these 87 populations⁷. These populations have unique genetic variants and linkage disequilibrium (LD)

patterns. Additionally, previous studies have shown that combining eQTLs from different ancestries can enable fine-mapping of causal variants and uncover potential novel mechanisms of brain disorders^{8,9}. Thus, the question of how to effectively leverage difference to uncover potential novel mechanisms of brain disorders is a significant topic in the field.

92 To enhance the diversity in brain eQTL mapping and improve the interpretation of SCZ GWAS 93 across populations, we performed brain eQTL mapping in three major ancestries. Our data pool 94 comprised genotype and RNA-seq data of AA (n= 158) and EUR (n= 408) from the 95 PsychENCODE Consortium and EAS (n= 217) from the Chinese Human Brain Bank 96 (Supplementary Table 1). We juxtaposed non-EUR results against EUR to systematically examine 97 differences and similarities in the brain eQTLs. Further, we investigated the contributing factors 98 for eQTL differences across populations. By applying diverse population brain eQTLs to TWAS 99 and colocalization analysis of SCZ GWAS, we identified new risk genes and pathways. Lastly, we 100 identified likely causal variants by multi-ancestry fine-mapping. The two key questions we sought 101 to answer are: 1) what drives the brain eQTL differences across populations? 2) what do we gain 102 by studying brain eQTLs in diverse populations?

103 **Results**

To capture brain eQTLs across diverse populations, we utilized high-density genotype data alongside high-throughput RNA-sequencing from prefrontal cortices. We derived AA (n = 158) and EUR (n = 408) data from the BrainGVEx project of the PsychENCODE Consortium. We generated EAS (n = 217) data from the Chinese Human Brain Bank (Fig. 1). Following rigorous quality checks and preprocessing (Extended Data Fig. 1 and Extended Data Fig. 2), we compiled expression data for 18,939 genes and genotype data at 6.4 million autosomal single nucleotide

polymorphisms (SNPs) across the three groups. Aligning the samples with the 1000 Genomes
Project reference populations, principal component analysis (PCA) confirmed the ancestry origins
of donors (Fig. 2a). We ensured sample identity consistency by comparing the genotypes from the
DNA and RNA samples. See methods for additional details.

Characterizing the cis-acting eQTLs in European, East Asian, and African American population

116 We separately conducted cis-eOTLs mapping in the EUR, EAS, and AA samples using a 5% 117 empirical gene-level false discovery rate (FDR) threshold. This yielded 1,966,209 significant 118 eQTL signals covering 11,622 genes (eGenes) and 1,226,769 SNPs (eSNPs) across the populations 119 (see Fig. 2b and Supplementary Table 2). Specifically, we identified 1,616,818 eQTL signals 120 spanning 10,236 eGenes and 1,025,004 eSNPs for EUR; 562,058 eQTLs incorporating 5,000 121 eGenes and 416,025 eSNPs for EAS; and 143,736 eOTLs covering 3,039 eGenes and 121,079 122 eSNPs for AA. To identify credible SNP sets harboring plausible causal variants in cis-eQTLs, we applied a fine-mapping method named SuSiE¹⁰ to each population's eQTL results. The results 123 124 showed 966 credible SNP sets for 757 eGenes in the EUR cohort, 826 sets for 726 eGenes in EAS, 125 and 847 sets for 746 eGenes in AA (Supplementary Tables 3-5). 126 To investigate the genomic features of these cis-eQTLs, we evaluated the SNP distributions and

125 To investigate the genomic reduces of these ets eq.(123), we evaluated the BAT distributions and 127 locations relative to various functional regions. 20% of cis-eQTLs in both EUR and non-EUR 128 populations were located within 10kb of transcription start site (TSS) regions (Fig. 2c). According 129 to the chromatin states predicted by Genomic Regulatory Elements and Gwas Overlap algoRithm 130 (GREGOR)¹¹ for prefrontal cortical tissue, eSNPs from the non-EUR populations were 131 significantly enriched in TSSs, promoters, and transcribed regulatory promoters or enhancers

132 $(P_{Bonferroni} < 0.05)$, identical to the observation in the EUR data. Moreover, using transcription 133 factor binding site (TFBS) annotation for 51 TFs, 46 and 49 TFs were significantly enriched with 134 cis-eQTLs in the AA and EAS populations respectively ($P_{Bonferroni} < 0.05$). All these TFBS were 135 also significantly enriched with cis-eQTLs in the EUR population. 136 To maximize the power of our population-based datasets, we employed METAL to amalgamate 137 the cis-eQTLs data from all three populations. This meta-analysis generated 598,193 eQTLs, 138 correlating 436,456 eSNPs with 5,209 eGenes (with a stringent P<2.5e-6) as depicted in Fig. 139 2b. However, meta-analysis does not consider the LD differences among the populations. We thus 140 used SuSiEx¹⁶ to identify likely causal variants regulating expression by incorporating the LD 141 reference data from different populations. In total, SuSiEx identified 2,121 credible SNP sets for 142 1,801 eGenes in the 3-population combined data. Further details from the meta-analysis and fine-143 mapping results can be found in Supplementary Table 6.

144 Population shared eQTLs showed similar regulatory effect across population

145 To evaluate the effect sizes across populations, we conducted a correlation test of effect size values 146 between the EUR and non-EUR populations. The effect sizes of the shared eQTLs between the 147 non-EUR and EUR were highly concordant (0.910 for eQTLs comparing EAS to EUR and 0.944 148 for AA to EUR; Fig 3a). To assess the robustness of the concordant effect size, we examined eQTL 149 slopes in the different populations. We looked at eQTLs obtained from the nominal, permutation, 150 and conditional tests, separately. eQTLs with smaller p-values or larger effect sizes showed greater 151 consistency across populations (Extended Data Fig. 3). Considering that sample size and 152 heterogeneity may influence the results, we randomly down-sampled the EUR data to match the 153 size of the non-EUR data. The results were similar to the results comparing all samples, showing

highly concordant effect sizes across populations (see Fig. 3c, Extended Data Fig. 3). In addition, we compared the slope of the down-sampled EUR data with GTEx data (also of EUR). We randomly sub-sampled 100 times and obtained a distribution of correlation values (R^2). The mean R^2 was 0.94, which was not significantly different from the correlation between the EUR and non-EUR population. We therefore concluded that the effect sizes of eQTLs in diverse populations were mostly stable across human populations.

160 We evaluated the replicated rate (π_1), which gauges the true positive rate for the eQTLs identified 161 in the non-EUR populations that were also associated in the EUR population. The replicated rate 162 was $\pi_1(\text{EAS-EUR}) = 0.86$ and $\pi_1(\text{AA-EUR}) = 0.91$ (see Fig.3b). The π_1 for the non-EUR 163 populations in EUR was slightly but significantly lower than the π_1 between two EUR cohorts, as 164 represented by the GTEx cis-eQTL data (prefrontal cortex) in our EUR eQTL data (π_1 (GTEx-EUR = 0.86, p-value = 0.023). To ensure a fair comparison of the replication rate of detected cis-165 166 eQTLs in non- EUR data, we adjusted the EUR data to reflect the smaller sample size of the non-167 EUR data. This adjustment enabled us to determine how many non-EUR cis-eQTLs were 168 confirmed in the adjusted EUR dataset. The adjusted results revealed a concordant trend: the 169 replicated rate between different populations was still slightly lower than that within the same 170 population assuming the same sample size (EUR-nonEUR average $\pi_1 = 0.68$, EUR_{adjusted}-EUR 171 average $\pi_1 = 0.72$, p-value = 0.037) (see Fig. 3d).

Population differences in brain cis-eQTLs are mainly caused by differences in SNP allele frequency while differences in effect size are small and uncertain

174 Here we defined those eQTLs that were exclusively observed in a single population as population-175 specific eQTLs. Upon analyzing the cis-eQTLs overlapping between populations, we identified 176 343,737 cis-eQTLs that were exclusively observed in the non-EUR populations, as detailed in 177 Supplementary Table 2. This number represents approximately 17% of all eQTL pairs. These 178 eQTLs involved 1,276 genes (about 10% of all eGenes) and 198,769 SNPs (around 16% of all 179 eSNPs, Fig. 2d-f.). Specifically, there were 292,254 cis-eQTLs involving 165,300 eSNPs and 937 180 eGenes that were observed only in the EAS population and 51,483 cis-eQTLs involving 33,469 181 eSNPs and 339 eGenes that were observed only in the AA population.

182 To further characterize these non-EUR-specific eQTLs, we analyzed the variance, taking into 183 account both the eOTL slope (effect size) and differences in allele frequency between populations. 184 We found that more than 90% of the population differences in variance were attributable to 185 differences in allele frequency. Moreover, to delve deeper into the distinctive characteristics of the 186 eQTLs exclusive to the non-EUR groups, we leveraged two statistics, the fixation index (FST) and 187 the minor allele frequency (MAF), retrieved from the 1000 Genomes Selection Browser¹². A high 188 FST value indicates that the measured locus has diverged over time in the populations. As expected, 189 eSNPs detected only in the EAS or AA population displayed a significantly elevated FST when 190 juxtaposed against eSNPs shared across populations (Wilcoxon test P < 2.2e-16). Meanwhile, the 191 non-EUR-specific eSNPs showed higher MAF values in their respective source populations 192 (Wilcoxon test P < 2.2e-16;) than in EUR. Of the 343,737 eQTLs absent in the EUR data, 309,363

193	were likely due to inadequate statistical power because they have smaller MAF in the EUR than
194	non-EUR population. Furthermore, 70,980 were rare in the EUR population (MAF _{1KG} < 0.05).

195 For the rest the eQTLs for which population differences could not be explained by differences in 196 MAF, a test for differences in eQTL slopes (effect sizes) was also conducted between the EUR 197 and non-EUR populations. The z-score of each independent eQTLs from conditional analysis was 198 calculated based on effect size and its standard deviation. Here the null hypothesis was that the 199 difference in eQTL effect size between the populations equals zero. No eQTL pairs detected by 200 conditional analysis could reject the null hypothesis. We then investigated if any eQTLs exhibited 201 opposite effect directions across populations. None of the independent eQTLs from the conditional 202 analysis displayed such effects. We relaxed our eQTL threshold using a nominal p-value < 0.05. 203 Only 534 eQTLs involving eighteen genes exhibited opposing eQTL effects between the EUR and 204 non-EUR populations. For example, the bitter taste receptor gene TAS2R31 showed opposite 205 directions of eQTLs in EAS and EUR (Fig. 3e), which could be replicated using the blood eQTLs 206 from a previous study 7,13 .

In conclusion, the variance in population differences can be largely attributed to differences in allele frequency. The influence of effect size differences, on the other hand, appears to be minimal and inconclusive.

210 Brain eQTLs from matched population can improve interpretation of SCZ GWAS

To determine if eQTLs detected from a specific population could explain the disease GWAS signals and SNP-based disease heritability better than eQTLs from non-matching populations, we undertook a two-step analysis. Firstly, we gathered SCZ GWAS summary statistics for the EUR, EAS, and AA populations from previously published studies^{14–16}. We employed the partitioned LD-score regression (LDSR)¹⁷ approach to assess the GWAS signal enrichment of these eQTLs.
eQTLs identified in the EAS population demonstrated a markedly higher enrichment in EAS-based
GWAS signals than eQTLs identified in the EUR population. Conversely, eQTLs identified in the
EUR population showed a greater enrichment for EUR-based GWAS signals than the eQTLs from
the EAS cohort. Both of these enrichments were statistically significant (Welch Modified TwoSample t-Test P-value < 0.001, Fig. 4a and 4b).

Besides the SNP heritability enrichment of all eQTLs, we also compared the significance of the GWAS signals for population-unique eSNPs. We found that population-unique eSNPs tended to have smaller p-values of disease association (i.e., stronger associations) in the corresponding population than in the mismatched population (Welch Modified Two-Sample t-Test P < 0.001), indicating the ability of population-unique eSNPs to explain the disease association and propose the relevant gene, which will be missed when only one population is studied.

227 SCZ risk genes identified using eQTLs and GWAS from non-EUR population

To uncover risk genes and pathways for SCZ in non-EUR populations, we used TWAS, regulatory Trait Concordance (RTC)¹⁸, and summary data-based mendelian randomization (SMR)¹⁹ to prioritize SCZ candidate risk genes in non-EUR populations and compared them with risk genes identified in the EUR (see Methods). In total, we prioritized ten risk genes in the EAS (Supplementary Tables 7-9). It is worth noting that our TWAS analysis of AA data did not reveal any significant associations. This lack of association in AA data might be attributed to the relatively small sample size available from the AA SCZ GWAS.

235 Seven SCZ candidate risk genes (SFXN2, RP11-282018.3, CYP17A1, VPS37B, DENR, FTCDNL1,

and *NT5DC2*) uniquely discovered in the EAS population were assessed for allele frequency. From

237 these seven genes, two of them were located in chromosome 10 and five of them were located in 238 the chromosome 12. The eSNPs for these genes showed lower allele frequency in the EUR 239 population than in EAS. For instance, the GWAS signal chr12:123286491:A:G in the gene 240 VPS37B was found to be significant in the EAS population with a high AF of 0.48. In contrast, 241 this association was not significant in the EUR population with a markedly lower allele frequency 242 of 0.04. A parallel pattern emerged with the eSNP for *VPS37B*, with a markedly higher frequency 243 (chr12:123306558:G:A, MAF=0.24) in EAS than in the EUR (MAF = 0.04). These results further 244 confirm that allele frequency differences between populations can explain most of the 245 discrepancies between the EUR and EAS GWAS and the eQTL results (Supplementary Table 10).

Novel potential SCZ regulatory variations were refined utilizing brain eQTLs from nonEUR population

248 Three of the ten risk genes identified in the EAS population were shared with the EUR population 249 (CNNM2, C12orf65, and MPHOSPH9), but differences in genetic architecture between 250 populations were still apparent. For example, two distinct significant SNPs in EAS and in EUR 251 were associated with SCZ on chromosome 10 (GWAS_{EUR}: chr10:104850632:G:A with GWAS p-252 value = 6.4E-13; GWAS_{EAS}: chr10:104657300:T:C with GWAS p-value = 5.4E-12). Using 253 eQTLs with GWAS signals in EAS and EUR separately, colocalization and SMR analysis 254 prioritized these two distinct GWAS SNPs to the same risk gene CNNM2 in the two populations, 255 respectively.

To further investigate if these signals are located within any regulatory elements, we utilized the non-coding variant annotation database $(NCAD)^{20}$ to annotate their regulatory information. Our findings revealed that all the EAS GWAS risk SNPs are situated in enhancer regions

259 (Supplementary Table 11). The EAS GWAS risk SNPs near the CNNM2 showed the strongest 260 evidence. Furthermore, we used the Lineage-specific Brain Open Chromatin Atlas²¹ to investigate 261 whether this enhancer region shows different effects in major brain cell types. The results did not 262 show any cell type differences, which indicates the enhancer effect exists universally in major 263 brain cell types (Extended Data Fig. 4a-c). Integrating these insights, we discovered strong 264 evidence for multiple regulatory regions among the EAS eSNPs-chr10:104654577:T:C, which 265 have a high LD with CNNM2 GWAS SNPs (LD $R^2 = 1$, p-value < 0.00001). Additionally, our 266 dual luciferase reporter assay results confirmed that the EAS eSNPs C-allele at chr10:104654577:T:C significantly enhances luciferase activity compared to the reference vector, 267 268 as detailed in the Extended Data Fig. 4d-e.

269 High-confidence putative causal variants of SCZ using multi-ancestry brain eQTLs

270 To identify high-confidence putative causal variants from multiple populations, we applied 271 colocalization to our fine-mapped eQTLs and SCZ GWAS signals. In total, we identified four 272 SNP-gene-disease triplets in which the SNP colocalized with both gene expression and SCZ 273 GWAS (Supplementary Table 12, PiPcoloc = $PiP_{GWAS} \times PiP_{cis-eOTLs} > 0.1$). The top genes with 274 PIP_{coloc} > 0.1 include FURIN, ZNF823, RHOA, and VWA5A (Fig. 4c). As an example, we identified 275 the strongest putative SCZ causal SNP for FURIN-chr15:91426560:G:A. This SNP is located in 276 the 3' untranslated regions (UTRs) of FURIN. Notably, this variant did not reach genome-wide 277 significance in the EAS population (P = 1.06E-3) likely due to limited statistical power. Our result 278 strongly supported that this causal variant is shared across populations, with causal probabilities 279 of 1. Previous study has also implicated the variant in both the EUR and EAS populations¹³.

280 **Discussion**

281 In this study, we have created a brain transcriptome resource and identified eQTLs in the prefrontal 282 cortex, specifically focusing on non-European populations. Our findings address the initial 283 inquiries raised in the introduction. Firstly, we investigated the driver behind the variation in brain 284 eQTLs across different populations. We found that differences in allele frequency and LD are 285 instrumental in connecting disease susceptibility to gene expression regulation. This finding 286 greatly augments our comprehension of genetic influences on gene expression in the human brain. 287 Secondly, when examining brain eQTLs from diverse populations, we gained power to explain the 288 GWAS heritability, uncover novel risk genes, and fine-map risk variants. We observed a 289 pronounced enrichment of disease heritability among eQTLs in matched populations. In the non-290 EUR cohort, the allele frequencies and LD configurations facilitated the identification of seven 291 novel SCZ risk genes. Additionally, we identified four high-confidence putative causal SCZ 292 variants. These results highlight the utility of studying non-European cohorts.

293 Population differences appear to be more pronounced at the allele frequency level but are less so 294 at the effect size level. In general, the estimated π_1 of eQTLs from non-EUR populations in EUR 295 is lower compared to the rate observed between down-sampling-EUR and the EUR population 296 cohort. Despite the relatively small sample size and statistical power, we still detected a significant 297 number of 343,737 cis-eQTLs including 232,254 EAS eQTLs and 51,483 AA eQTLs that were 298 significant only in the non-EUR populations. While over half of eSNPs in our non-EUR dataset 299 were population-unique, 80% of eGenes identified in the non-EUR were also eGenes in the EUR 300 data, but associated with different SNPs. The consistency of our observations with prior research 301 involving diverse populations, including studies on gene expression^{22,23}, methylation²⁴, and 302 chromatin accessibility²⁵, confirms the shared regulatory patterns across different populations.

303 Interestingly, some eQTLs showed contrasting effects across populations. ~0.1% of the non-EUR-304 specific eQTLs displayed opposing directions in effect size. A notable example of this is the eQTL 305 rs2599400-*TAS2R31*, which showed opposite effects in different populations. Blood eOTLs from 306 EAS²⁶, EUR, and AFR⁷ also support this observation. Prior studies have underscored the 307 population-specific variations in TAS2R31, linking these variations to differing sensitivity to the 308 bitter taste²⁷. It is important to further investigate these discrepancies in gene expression regulation 309 among populations as they influence phenotypes. However, it should be noted that lack of 310 replication across all these studies limited our power to detect opposite-effect eQTLs.

311 Our findings underscore that enhancing genetic ancestral diversity is more efficient for power gain 312 than increasing the sample size within large-scale eQTLs datasets. Through our benchmarking of 313 eQTLs across three populations, we have established robust capabilities for identifying eQTLs 314 with a MAF greater than 0.2 and an effect size of 0.6 (Extended Data Fig. 5). Our power analysis 315 indicates that more than 30,000 individuals of European ancestry is needed to uncover all eQTLs 316 with MAF of 0.01 in this population, based on the estimated effect size of eQTLs exclusively 317 observed in non-EUR populations (Extended Data Fig. 5). For example, one the eQTL pair 318 (chr12:123306558:G:A-VPS37B) would require 3,215 EUR samples based on the power estimate 319 because of the low frequency in the EUR population (MAF = 0.04). However, the MAF of this 320 eSNP is 0.22 in EAS, which reduces the required sample size from 3,215 to 246. Thus, 321 incorporating a more diverse population would not only reveal numerous regulatory variants that 322 are rarer in EUR but more prevalent in non-EUR groups. Advancing towards a broader, more 323 diverse human reference dataset will facilitate more comprehensive investigations into the impact 324 of human demography on eQTL detection, thereby deepening our understanding of the distribution 325 and influence of genetic regulation in the human brain.

326 Differences in the genetic architecture underlying gene expression can help us to prioritize new 327 risk genes. Notably, prior research has reported that disease-associated loci tend to be skewed 328 towards variants with higher allele frequency in the discovery population, indicating that limited 329 statistical power may result in "missing" disease-association signals. Incorporating diverse 330 samples can enhance our ability to uncover the etiology of the disease. In our study, we identified 331 seven new SCZ risk genes using the non-EUR population, including VPS37B in the EAS 332 population. VPS37B is associated with calcium-dependent protein binding, providing new 333 evidence to support the involvement of the calcium-related pathway in SCZ risk in the EAS 334 population²⁸. Another interesting candidate highlighted in our study was CYP17A1 (RTC = 0.99). 335 The corresponding GWAS signal was significant in the EAS and EUR populations ($P_{EAS} = 4.5E$ -336 8; MAF_{EAS} = 0.48; P_{EUR} = 2.6E-13; MAF_{EUR} =0.30), while the corresponding eSNP in EAS 337 population (MAF=0.48) showed extremely low frequency in EUR population (MAF<0.001). 338 CYP17A1 notably serves as an enzyme important for the production of glucocorticoids and sex 339 hormones, such as estrogen, which have been linked to schizophrenia^{29–31}.

Besides enhancing the power for detecting risk genes, the inclusion of brain eQTLs from diverse populations improves the ability to fine-map SCZ GWAS loci, identifying new regulatory variants which have the potential to regulate downstream gene expression. This approach aids in interpretation, thereby facilitating subsequent computational and experimental functional investigations. Our result revealed a potential novel regulatory region near the population-shared risk gene *CNNM2*. This discovery showcases the power of leveraging diverse populations.

By leveraging the multi-ancestry information, trans-ancestry fine-mapping also helped us identify
high-confidence putative causal variants. In addition to previously validated genes, our study
uncovered another significant finding at chr3:50297330:A:G-*RHOA*-SCZ through trans-ancestry

colocalization. *RHOA* encodes a member of the Rho family of small GTPases, pivotal in signal
transduction cascades by toggling between inactive GDP-bound and active GTP-bound states.

351 Some limitations of our study merit attention. Our sample size is still relatively small. Our analysis 352 suggests that expanding the sample size would capture a larger set of eQTLs. The small sample 353 size could have significantly impacted the comprehensiveness of our findings. The modest sample 354 size of the AA eQTL dataset and the SCZ GWAS cohort likely led to the failure of TWAS in the

355 AA population.

In conclusion, we presented a novel genome-wide map of human brain gene expression regulation. Importantly, this resource bridges the gap between neuropsychiatric GWAS and brain gene expression profiling in non-European populations. Our study emphasizes the significance of this new atlas of brain gene expression regulation in non-European populations for advancing our understanding of human diversity, addressing health disparities, and developing precision medicine.

362 Materials and methods

363 Sample collection and sequencing

We collected 217 prefrontal cortical samples of Han Chinese ancestry from the National Human Brain Bank for Development and Function^{32,33}; the samples were handled according to the standardized operational protocol of the China Human Brain Banking Consortium, under the approval of the Institutional Review Board of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (Approval Number: 009-2014).

We sequenced 217 samples following the BGISEQ-500 protocol outsourced to BGI. 1µg genomic DNA was randomly fragmented by Covaris, the fragmented DNA was selected by Agencourt AMPure XP-Medium kit to an average size of 200-400bp, followed by adapter ligation, PCR amplification, and the products were recovered by the AxyPrep Mag PCR clean up kit. The doublestranded PCR products were heat-denatured and circularized by the splint oligo sequence. The single-strand circle DNA (ssCir DNA) was formatted as the final library and qualified by QC. Sequencing was performed on BGISEQ-500 platform with an average depth of 10X.

376 Total RNA was extracted from the brain tissue using Trizol (Invitrogen, Carlsbad, CA, USA) 377 according to manufacturers' instructions. Then, total RNA was qualified and quantified using a 378 Nano Drop and Agilent 2100 bioanalyzer (Thermo Fisher Scientific, MA, USA). Ribo-zero 379 method was used to remove the rRNA. Purified mRNA was fragmented into small pieces with 380 fragment buffer at an appropriate temperature. The cDNAs were purified by magnetic beads. After 381 purification, A-Tailing Mix and RNA Index Adapters were added by incubating to carry out end 382 repair. The cDNA fragments with adapters were amplified by PCR, and the products were purified 383 by Ampure XP Beads. The library was validated on the Agilent Technologies 2100 bioanalyzer 384 for quality control. The final library was amplified with phi29 (Thermo Fisher Scientific, MA, 385 USA) to make DNA nanoball (DNB), DNBs were loaded into the patterned nanoarray and single 386 end 50 base reads were generated on BGISEQ500 platform.

387 Data quality control

Raw sequencing reads were filtered to get clean reads by using SOAPnuke $(v1.5.6)^{34}$, and FastQC³⁵ was used to evaluate the quality of sequencing data via several metrics, including sequence quality per base, sequence duplication levels, and quality score distribution for each

391 sample. The average quality score for overall DNA and RNA sequences was above 30, indicating392 that a high percentage of the sequences had high quality.

393 Variant identification

Clean DNA sequencing reads were mapped to the human reference genome hg19 (GRCh37) using
BWA-MEM algorithm (BWA v. 0.7.128)³⁶. Ambiguously mapped reads (MAPQ <10) and
duplicated reads were removed using SAMtools v. 1.29³⁷ and PicardTools v. 1.1 respectively.
Genomic variants were called following the Genome Analysis Toolkit software (GATK v. 3.4.4.6)
best practices.

399 Population validation, imputation, and filtering

We used PLINK to infer the genomic ancestry of each sample in this study by combining our genotype data and the genotype data from the 1000 Genomes Project³⁸; no sample was excluded. Using Michigan Imputation Server⁴¹, EAS genotypes were imputed into the 1000 Genomes Project phase 3 EAS reference panel by chromosome and subsequently merged. Imputed genotypes were filtered for LD R² < 0.3, Hardy-Weinberg equilibrium p-value < 10e-6 and MAF < 0.05, resulting in ~ 6 million autosomal SNPs.

For AA population, genotypes were imputed into the 1000 Genomes Project phase 3 AA reference panel by chromosome and subsequently merged. To further confirm the ancestry of the African American samples, all AA samples were evaluated for their ancestry with three broad population groups with $PC1 \ge 25\%$ AFR and < 25% AMR, < 25% EAS, < 25% SAS; clustering of individuals in each broad population group with the 1000 Genomes Project reference populations are shown in Fig.2a.

412 Sex check and sample swap identification

The sex of each sample was inferred with SNPs using PLINK. In the EAS cohort, two samples were identified as sex-mismatched and were subsequently removed in downstream analysis. Quality control was performed on genotypes using sample Binary Alignment Map (BAM) files to detect any sample identity swaps between the RNA and DNA experiments. The QTLtools match function³⁹ confirmed that all samples were appropriately matched.

418 Gene expression quantification and quality control

The RNA-sequencing reads were mapped using STAR $(2.4.2a)^{40}$ and the genes and transcripts quantification was performed using RSEM $(1.3.0)^{41}$. Raw read counts were log-transformed using R package VOOM⁴², thereafter filtering those with log2(CPM) < 0 in more than 75% of the samples. Mitochondrial DNA and X and Y chromosome-derived transcripts were excluded. Samples with a Z-score (measured for inter-sample connectivity) less than -3 were also discarded. Finally, quantile normalization was utilized to equalize distributions across samples.

425 Covariate selection

426 To measure technical covariates, quality control metrics were collected using STAR, PicardTools 427 v1.139 and RNASeQC. Principal components of the metrics data were calculated and included as 428 SeqPCs for covariate selection. Hidden covariates were measured using probabilistic estimation of expression residuals (PEER)⁴³ and found to be significantly correlated with technical and 429 430 biological covariates such as experimental batch, RNA Integrity Number (RIN), sex, and age of 431 death. Based on the Bayesian information criterion (BIC) score, redundant covariates were 432 removed to avoid overfitting. A forward and backward selection procedure was followed, and 433 PEER hidden factors and known covariates were added. The covariate with the higher BIC score 434 was selected for subsequent QTL mapping. PEER was run with varying numbers of inferred 435 hidden factors: 5, 10, 15, 20, 25, 30, 35, 40, 45 and 50, independently.

436 cis-eQTL mapping

437 Cis-eQTL mapping was performed using QTL tools, accounting for PEER factors, with a defined 438 cis window spanning one megabase upstream and downstream of the gene/intron cluster body. 439 Using the PEER from gene expression matrix, twenty hidden covariates were identified and 440 adjusted. To detect all available QTLs, QTL tools was conducted in nominal pass mode. To identify 441 the best nominal associated SNP per phenotype, QTL tools was executed in the permutation pass 442 mode. Additionally, to identify SNPs with independent effects on regulating gene expression, 443 QTL tools was run in the conditional pass mode. SNPs with P-values below the threshold of the 444 permutation threshold is classified as significant QTLs.

To address potential sample size disparities that could impact the results, the EUR data were randomly sampled with various sample size (150, 200, 250, 300, 350, and 400) and applied the same analytical pipeline while exploring the relationship between sample size and number of QTLs.

448 eQTL meta-analysis

The SNP-gene pairs with a genome-wide P value reaching the threshold of 10e-6 for each population were collected and performed the meta-analysis. Standard fixed-effects meta-analysis were used to combine all data into a single regression model by METAL⁴⁴. The meta-analysis assumes a fixed-effects size, as well as constant error variance, across all data.

453 eQTL fine-mapping

The initial step of fine-mapping involved using the in-sample LD of the three populations. We extracted common variants with MAF > 5% from each group and used PLINK to determine the LD regions of these common variants for each population. To eliminate strand flipping and alignment issues, multi-allelic variations and indels were removed. Next, SuSiEx was applied to 458 merge the eQTLs summary statistics from the three groups. Credible set is defined as a set of 459 putative causal variants. A credible set was discarded if it lacked genetic variants reaching genome-460 wide significance (p < 1e-6) in either the population-unique eQTLs or cross-population meta-461 eQTLs. By considering prior knowledge and the observed data, this method provides a posterior 462 probability (PIP) for each variant being the causal one in the associated region. Variants with high 463 PIPs are then considered strong candidates for functional follow-up studies.

464 **Functional enrichment**

To determine functional enrichment, GREGOR⁴⁸ was performed to test the eQTL enrichment. GREGOR calculated the enrichment value based on the observed and expected overlap within each annotation. To conduct our analysis, the 15-state ChromHMM model BED (Browser Extensible Data) files from the Roadmap Epigenetics Project⁴⁵, and 78 consensus transcription factor and DNA-protein binding site BED files existing in multiple cells were downloaded. Fifty binding proteins showed cortical brain expression in EAS and AA populations data⁴⁶.

471 The fraction of shared eQTLs between non-EUR and EUR populations

472 Sharing rate was assessed based on significant eQTLs in the discovery dataset by estimating the 473 proportion of true associations (π_1) on the distribution of corresponding p-values of the overlapping 474 eQTLs in the replication dataset⁴⁷.

475 **F**_{ST} and MAF analysis

Fixation index (F_{ST}) was estimated using vcftools following the Weir and Cockerham approach for each eSNP⁴⁸. The population-divergent SNPs were defined as those with $F_{ST} \ge 0.05$ and population-shared SNPs as those with $F_{ST} < 0.05$. To generate the list of population-unique QTLs

and population-shared QTLs, we collected the overlap of eQTLs from the pairwise comparisons
of the list of AA eQTLs, EAS eQTLs, and EUR eQTLs. Finally, Fisher's exact test was performed
between population-unique QTLs and population-shared QTLs to test the contribution of MAF in
the QTL comparison.

483 Variance explained

Variance explained, which combines the effect size (beta) and frequency of the allele (f), can be considered an approximate measure of a causal variant's importance within a population. Variance is approximated using the formula $2f(1 - f)\log(beta)^2/(\pi^2/3)^{49}$. Although these variants often exhibit similar odds ratios across populations, their allele frequencies may differ. By considering both the effect size (OR) and the frequency of the risk allele (f), the variance explained offers a valuable approximation of a causal variant's significance within a given population.

490 **Power estimation**

491 We used R to calculate the sample size needed to achieve a given power level in a chi-square test, 492 based on an assumed effect size and a significance threshold. This analysis starts by setting initial 493 values for power, effect size, and p-value threshold. Then, the critical chi-square statistic required 494 to meet the power level is computed. A function, *calculate ncp*, is defined to calculate the non-495 centrality parameter from the p-value and degrees of freedom, adjusting for the critical chi-square 496 statistic. Subsequently, the non-centrality parameter is computed for the given power and p-value 497 threshold. Another function, af *n* relation, is created to determine the relationship between allele 498 frequency and sample size, incorporating the effect size and the non-centrality parameter. Finally, 499 the code iteratively solves for the sample size corresponding to a range of allele frequencies, thus

enabling the determination of the necessary sample size for different allele frequencies to maintainthe specified power level in the chi-square test.

502 Partitioned LDSR

Partitioned LD score regression v1.0.1⁵⁰ was used to measure the enrichment of GWAS summary 503 504 statistics in each functional category by accounting for LD. Brain QTL annotations were created 505 by eSNP, mapped to the corresponding 1000 Genome reference panel. LD scores were calculated 506 for each SNP in the QTL annotation using an LD window of 1cM in 1000 Genomes European 507 Phase 3 and 1000 Genomes Asian Phase 3 separately. Enrichment for each annotation was 508 calculated by the proportion of heritability explained by each annotation divided by the proportion 509 of SNPs in the genome falling in that annotation category. We then applied Welch Modified Two-510 Sample t-Test on enrichment values generated from QTLs in the two populations.

511 Colocalization

Conditional association was used to test for evidence of colocalization. This method compares the p-value of association for the lead SNP of an eQTL before and after conditioning on the GWAS hit. The equation for the regulatory trait concordance (RTC) Score is as follows: RTC= (N_{SNPs} in an LD block/Rank_{GWAS_SNP})/ N_{SNPs} in an LD block. The rank denoted the number of SNPs, which when used to correct the expression data, has a higher impact on the QTL than the GWAS SNPs. RTC values close to 1.0 indicated causal regulatory effects. A threshold of 0.9 was used to select causal regulatory elements.

519 Colocalization of fine-mapped variations from complex traits and cis-eQTL correlations were 520 performed. Based on complex trait and cis-eQTL fine-mapping data, a posterior inclusion

- 521 probability of colocalization for a variant was calculated as a product of PIP for GWAS and PIP
- 522 for the cis-eQTLs (PIPcoloc = $PIP_{GWAS} * PIP_{cis-eQTLs}$).

523 Summary-data-based Mendelian randomization

SMR¹⁹ was applied on SCZ GWAS summary data to prioritize candidate genes. Significant OTLs 524 525 identified in the previous analysis (FDR < 0.05), were combined with filtered GWAS summary 526 data (p < 5e-8) to perform the SMR test. In general, we used the default parameters suggested by 527 the developers of the SMR software. These included the application of heterogeneity independent 528 instruments (HEIDI) testing, filtering out hits that arose from significant linkage with 529 pleiotropically associated variants (LD cutoff of P = 0.05 in the HEIDI test, as suggested by SMR). 530 Genes with an empirical P that passed Bonferroni correction in the SMR test and a P > 0.05 in the 531 HEIDI test were considered as risk genes.

532 Prioritizing genes underlying GWAS hits using TWAS

In this research, we initially developed gene expression prediction models for distinct populations using MetaXcan software⁵¹. Following this, we integrated these models with GWAS (Genome-Wide Association Studies) summary statistics specifically focused on schizophrenia. This integration aimed to generate gene-level z-scores representing the association of the geneticallydetermined expression for a gene from its prediction model with the phenotype. TWAS enabled us to compute P-values and subsequently prioritize genes in relation to their association with schizophrenia risk.

540 **Plasmid construction**

541 We obtained the 55 bp SNP-centered DNA sequence from UCSC Genome Browser 542 (GRCh38/hg38), then added the sticky end of restriction enzymes KpnI and NheI at both ends of

the 55bp sequence to synthesis primers. Primer annealing to obtained double-strand sequence and
then inserted into pGL3-Promoter Vector (Promega) using FastDigest enzymes (ThermoFisher)
and T4 DNA Ligase (Invitrogen). We valid the vector sequence using sanger sequence by primer
GLP2 and RVP3.

547 Dual Luciferase Reporter Assay

For transfection, we used SH-SY5Y and HS-683 cells to perform the experiments. Transfecting cells at 50-60% confluency, cells were co-transfected with 500ng reconstruction vector and 10ng pRL-TK using Lipofectamine 3000 Transfection Reagent (ThermoFisher) in 24 well plates. After 48h transfection, using Dual Luciferase Reporter Assay Kit (Promega) to measure the firefly luciferase activity and renilla luciferase activity, the luminescence was detected using Tube Luminometer (Berthold Sirius).



Fig. 1. Study design. We examined genotype and RNA-seq data from African Americans (AA),
Europeans (EUR), and East Asians (EAS) to identify expression quantitative trait loci (eQTLs)

557 unique to non-European populations and their role in schizophrenia risk.



Fig. 2: Identification and characterization of eQTLs. a) PCA plot showing the population structure of individuals in our study as well as the 1000 Genomes Project. AFR: African; AMR: American; EAS: East Asian; EUR: European; b) Circos manhattan plot of significant eQTL genes among the three populations with highlighted top 50 fine-mapped eGenes. d-f) Upset plot showed overlap among the significantly associated eQTL pairs (d) eGenes (e) as well as eSNPs (f) between populations.

576

577





Fig. 3: Analysis of the regulatory patterns. a) relationship between sample size and the # of detected eQTLs. b) Effect sizes for common (MAF> 1%) sentinel cis-eQTLs across EA and AA populations; c) Comparison of MAF between population-shared and non-EUR unique eSNPs; d) downsampling to estimate π_1 between non-European and European eQTLs . e) example of opposite effect eQTL *TAS2R31*- rs2599400.

- 585
- 586
- 587
- 588
- 589
- 590





Fig. 4: Explanation of SCZ GWAS signals and prioritization of candidate genes. a) integration
strategies; b) GWAS enrichment results from LDSR. ***: Welch Modified Two-Sample t-Test P
< 0.001; c) Fine-mapped colocalization results. Each point represents an eQTL pais, the x-axis
represents the GWAS pip for that eSNP, and the y-axis represents the eQTL pip for that eSNP.
Red points represent pip_{GWAS}*pip_{eQTL}>0.1 and are labeled with the eGene

603 Data availability

604 The raw sequence data reported in this paper have been deposited in the Genome Sequence 605 Archive in BIG Data Center, Beijing Institute of Genomics (BIG), Chinese Academy of Sciences, 606 under accession numbers HRA000108, HRA000108 that can be accessed at 607 https://bigd.big.ac.cn/gsa-human. eQTLs summary results can be downloaded while requesting to 608 the corresponding author.

609 Code availability

610 Codes are available at https://github.com/liusihan/population-compare-pipeline.

611 Acknowledgments

We thank all donors and their families. Tissue was provided by the Human Brain Bank, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, the Chinese Brain Bank Center, and the Xiangya School of Medicine Brain Bank. We acknowledge Stanley Center for Psychiatric Research for supporting Hailiang Huang and Yu Chen working on this project.

617 Funding

This study was supported by National Natural Science Foundation of China (Grants Nos. 82022024, 31571312, and 91632116), the National Key R&D Project of China (Grants No. 2016YFC1306000), The Science and Technology Innovation Program of Hunan Province (2021RC4018, 2021RC5027), and NIH grant 1R01MH126459-01A1.

622 Author contributions

623	Y.C. and S.L.	. wrote the man	uscript, ana	lyzed the dat	a and perfor	med all co	mputations.	F.W.	and

- 624 Y. J. contributed to eQTLs analysis of EUR population. Z.R., F.D., C.H and M.L. extracted DNA
- and RNA, as well as collected sample information. R.D., Y.X., and R.K. substantively revised the
- 626 manuscript. Z.N., S.X. and H.H. participated in the design of comparing the brain regulatory
- 627 architecture. K.Y., W.Q., C.M., X.Y., A.B., J.D., J.H., B.T. and C.L. provided primary sequenced
- 628 samples and data including their clinical information. C.M., C.L. and C.C. conceived, designed
- 629 and supervised the study and modified the manuscript.

630 **Conflict of Interest**

- 631 All the authors declare no competing financial interests.
- 632

633 Ethnics

- Ethics Committee of Central South University gave ethical approval for this work (2015031007).
- 635

637 **References**

- 638 1. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
 639 schizophrenia. *Nature* 604, 502–508 (2022).
- 640 2. Peterson, R. E. *et al.* Genome-wide Association Studies in Ancestrally Diverse Populations:
- 641 Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**, 589–603 (2019).
- 642 3. Hindorff, L. A. *et al.* Prioritizing diversity in human genomics research. *Nat. Rev. Genet.* 19, 175–185 (2018).
- 644 4. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* 45, 580–
 645 585 (2013).
- 5. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide
 range of complex diseases of middle and old age. *PLoS Med.* 12, e1001779 (2015).
- 648 6. Wang, L. et al. Brain Banks Spur New Frontiers in Neuropsychiatric Research and Strategies
- 649 for Analysis and Validation. *Genomics Proteomics Bioinformatics* **17**, 402–414 (2019).
- 650 7. Mogil, L. S. *et al.* Genetic architecture of gene expression traits across diverse populations.
- 651 *PLoS Genet.* **14**, e1007586 (2018).
- 652 8. de Klein, N. et al. Brain expression quantitative trait locus and network analyses reveal
- downstream effects and putative drivers for brain-related diseases. *Nat. Genet.* **55**, 377–388
- 654 (2023).
- 655 9. Zeng, B. *et al.* Multi-ancestry eQTL meta-analysis of human brain identifies candidate causal
 656 variants for brain-related traits. *Nat. Genet.* 54, 161–169 (2022).
- 10. Zou, Y., Carbonetto, P., Wang, G. & Stephens, M. Fine-mapping from summary data with
 the 'Sum of Single Effects' model. *PLoS Genet.* 18, e1010299 (2022).

- 659 11. Schmidt, E. M. *et al.* GREGOR: evaluating global enrichment of trait-associated variants in
 660 epigenomic features using a systematic, data-driven approach. *Bioinforma. Oxf. Engl.* 31,
 661 2601–2606 (2015).
- 12. Pybus, M. et al. 1000 Genomes Selection Browser 1.0: a genome browser dedicated to
- signatures of natural selection in modern humans. *Nucleic Acids Res.* **42**, D903-909 (2014).
- 13. Ning, Z. *et al.* Expression profiles of east-west highly differentiated genes in Uyghur
- 665 genomes. *Natl. Sci. Rev.* **10**, nwad077 (2023).
- 14. Lam, M. *et al.* Comparative genetic architectures of schizophrenia in East Asian and
- 667 European populations. *Nat. Genet.* **51**, 1670–1678 (2019).
- 668 15. Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics
- 669 Consortium. Electronic address: douglas.ruderfer@vanderbilt.edu & Bipolar Disorder and
- 670 Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genomic
- Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. *Cell* **173**,
- 672 1705-1715.e16 (2018).
- 673 16. Bigdeli, T. B. et al. Contributions of common genetic variants to risk of schizophrenia
- among individuals of African and Latino ancestry. *Mol. Psychiatry* **25**, 2455–2467 (2020).
- 675 17. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
 676 association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).
- 18. Nica, A. C. *et al.* Candidate causal regulatory effects by integration of expression QTLs with
 complex trait genetic associations. *PLoS Genet.* 6, e1000895 (2010).
- 679 19. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex
 680 trait gene targets. *Nat. Genet.* 48, 481–487 (2016).

- 20. Feng, X., Liu, S., Li, K., Bu, F. & Yuan, H. NCAD v1.0: A database for non-coding variant
 annotation and interpretation. *J. Genet. Genomics Yi Chuan Xue Bao* S1673-8527(23)00257–
 6 (2023) doi:10.1016/j.jgg.2023.12.005.
- 684 21. Fullard, J. F. *et al.* An atlas of chromatin accessibility in the adult human brain. *Genome Res.*685 28, 1243–1252 (2018).
- 686 22. Kachuri, L. et al. Gene expression in African Americans, Puerto Ricans and Mexican
- 687 Americans reveals ancestry-specific patterns of genetic architecture. *Nat. Genet.* 55, 952–963
 688 (2023).
- 23. Lappalainen, T. *et al.* Transcriptome and genome sequencing uncovers functional variation
 in humans. *Nature* 501, 506–511 (2013).
- 691 24. Fraser, H. B., Lam, L. L., Neumann, S. M. & Kobor, M. S. Population-specificity of human
 692 DNA methylation. *Genome Biol.* 13, R8 (2012).
- 693 25. Tehranchi, A. *et al.* Fine-mapping cis-regulatory variants in diverse human populations. *eLife*694 8, e39595 (2019).
- 695 26. Ning, Z. *et al.* Expression profiles of east-west highly differentiated genes in Uyghur
- 696 genomes. *Natl. Sci. Rev.* **10**, nwad077 (2023).
- 697 27. Wooding, S. P. & Ramirez, V. A. Global population genetics and diversity in the TAS2R
 698 bitter taste receptor family. *Front. Genet.* 13, 952299 (2022).
- 28. Andrade, A. *et al.* Genetic Associations between Voltage-Gated Calcium Channels and
 Psychiatric Disorders. *Int. J. Mol. Sci.* 20, 3537 (2019).
- 701 29. Heringa, S. M., Begemann, M. J. H., Goverde, A. J. & Sommer, I. E. C. Sex hormones and
- 702 oxytocin augmentation strategies in schizophrenia: A quantitative review. *Schizophr. Res.*
- 703 **168**, 603–613 (2015).

- 30. de Boer, J., Prikken, M., Lei, W. U., Begemann, M. & Sommer, I. The effect of raloxifene
- augmentation in men and women with a schizophrenia spectrum disorder: a systematic
- review and meta-analysis. *NPJ Schizophr.* **4**, 1 (2018).
- 31. Chiappelli, J. *et al.* Disrupted glucocorticoid--Immune interactions during stress response in
- 708schizophrenia. Psychoneuroendocrinology 63, 86–93 (2016).
- 32. Yan, X.-X., Ma, C., Bao, A.-M., Wang, X.-M. & Gai, W.-P. Brain banking as a cornerstone
 of neuroscience in China. *Lancet Neurol.* 14, 136 (2015).
- 711 33. Qiu, W. et al. Standardized Operational Protocol for Human Brain Banking in China.
- 712 *Neurosci. Bull.* **35**, 270–276 (2019).
- 713 34. Chen, Y. et al. SOAPnuke: a MapReduce acceleration-supported software for integrated
- quality control and preprocessing of high-throughput sequencing data. *GigaScience* 7, 1–6
 (2018).
- 716 35. Trivedi, U. H. *et al.* Quality control of next-generation sequencing data without a reference.
- 717 Front. Genet. 5, 111 (2014).
- 718 36. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform.
- 719 Bioinforma. Oxf. Engl. 25, 1754–1760 (2009).
- 37. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinforma. Oxf. Engl.* 25,
 2078–2079 (2009).
- 38. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based
 linkage analyses. *Am. J. Hum. Genet.* 81, 559–575 (2007).
- 39. Delaneau, O. *et al.* A complete tool set for molecular QTL discovery and analysis. *Nat.*
- 725 *Commun.* **8**, 15452 (2017).

- 40. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinforma. Oxf. Engl.* 29, 15–
 21 (2013).
- 41. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or
 without a reference genome. *BMC Bioinformatics* 12, 323 (2011).
- 42. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model
 analysis tools for RNA-seq read counts. *Genome Biol.* 15, R29 (2014).
- 43. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of
- expression residuals (PEER) to obtain increased power and interpretability of gene
- 734 expression analyses. *Nat. Protoc.* **7**, 500–507 (2012).
- 44. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
 genomewide association scans. *Bioinforma. Oxf. Engl.* 26, 2190–2191 (2010).
- 45. Roadmap Epigenomics Consortium *et al.* Integrative analysis of 111 reference human
- 738 epigenomes. *Nature* **518**, 317–330 (2015).
- 46. Arbiza, L. *et al.* Genome-wide inference of natural selection on human transcription factor
 binding sites. *Nat. Genet.* 45, 723–729 (2013).
- 741 47. Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. *Proc. Natl.*742 *Acad. Sci. U. S. A.* 100, 9440–9445 (2003).
- 48. Bhatia, G., Patterson, N., Sankararaman, S. & Price, A. L. Estimating and interpreting FST:
 the impact of rare variants. *Genome Res.* 23, 1514–1521 (2013).
- 49. Pawitan, Y., Seng, K. C. & Magnusson, P. K. E. How many genetic variants remain to be
 discovered? *PloS One* 4, e7969 (2009).
- 50. Finucane, H. K. et al. Heritability enrichment of specifically expressed genes identifies
- disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).

- 51. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene
- 750 expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).



754 Extended Data Figure 1: Overview of methods and QC pipeline for EAS samples.



- Extended Data Figure 2: Preprocessing of RNA-sequencing and whole-genome sequencing
- 757 (WGS) data of EAS samples. a, Sex-mismatch checked by WGS data. b, Population PCA plot
- 758 with 1000G genotype data. c, Imputation accuracy. d, Sex-mismatch checked by Xist expression.
- 759 e, PCA plot for EAS samples. f, Distribution of Z-score.



- 760 761 Extended Data Figure 3: Effect size correlation of population-shared eQTLs between EUR and
- 762 non-EUR population. (a-c) nominal pass; (d-f) permutation pass



- Extended Data Figure 4: Regulatory effect across glutamate neuron, GABA neuron,
- oligodendrocytes, and microglia for new regulatory SNPs within population-shared risk genes
- for (a) CNNM2, (b)C12orf65, (c) MPHOSPH9. (d) Dual luciferase reporter assay for EAS eSNP
- at risk gene CNNM2. (f) eQTL result for the eSNP and expression risk gene CNNM2 in EAS
- 768 cohort





diverse populations. (a) The percentage of brain eQTLs detected power under different

sample sizes and effect sizes is shown as a function of log-scaled sample size. (b) The

- required sample size achieving 80% power based on the effect size estimated form
- 774 non-EUR specific eQTLs.







а





TT TC CC (39) (75) (31 10_104654577_rs10883795_T_C











С



eQTL pairs







d





рор

🚔 EAS

📥 🗛

EUR





b

е



а







а